This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
8th Kitasato University-Harvard School of Public Health
Symposium on Advanced and GlobalSymposium on Advanced and GlobalDrug Development Techniques
"Learning from Experience and New Challenges for the Future"Tuesday September 30 2008
Global Clinical Trials of Medical DevicesGlobal Clinical Trials of Medical Devices
Tuesday, September 30, 2008ANA Intercontinental Tokyo, Room "Prominence"
Global Clinical Trials of Medical DevicesGlobal Clinical Trials of Medical Devices--Complementary Approach with Global Harmonization Task Force (GHTF) Complementary Approach with Global Harmonization Task Force (GHTF)
and Harmonization by Doing (HBD)and Harmonization by Doing (HBD)--
Global Clinical Trials of Medical DevicesGlobal Clinical Trials of Medical Devices-- Complementary Approach with Global Harmonization Task Force (GHTF) Complementary Approach with Global Harmonization Task Force (GHTF)
and Harmonization by Doing (HBD) and Harmonization by Doing (HBD) --
¤ Clinical Evaluation of Medical DevicesGHTF¤ GHTFGlobal Harmonization Task ForceGlobal Harmonization Task Force
¤ HBDHBDHarmonization by Doing
Juntendo University Medical School 2
8th Kitasato University - Harvard School of Public Health Symposium, September 30, 2008, Tokyo, Japan
Implantable Cardiac DefibrillatorImplantable Cardiac DefibrillatorAmiodarone or an Implantable Cardioverter-pDefibrillator for Congestive Heart Failure (SCD-HeFT)G.H. Bardy and others(N Engl J Med 2005; 352 : 225 - 37.)( g ; )
Bardy GH. N Engl J Med. 2005;352:225-237.
Global Clinical Trials of Medical DevicesGlobal Clinical Trials of Medical Devices-- Complementary Approach with Global Harmonization Task Force (GHTF) Complementary Approach with Global Harmonization Task Force (GHTF)
and Harmonization by Doing (HBD) and Harmonization by Doing (HBD) --
¤ Clinical Evaluation of Medical DevicesGHTF¤ GHTFGlobal Harmonization Task ForceGlobal Harmonization Task Force
¤ HBDHBDHarmonization by Doing
Juntendo University Medical School 4
8th Kitasato University - Harvard School of Public Health Symposium, September 30, 2008, Tokyo, Japan
Overview of PAL RegulationP M k t Ph
GHTF Classes
Risk-based Classification
Pharm. Affairs Law. QMS- Pre-Market Phase -
Classes ClassificationClass Mkt.
Auth.Sales
Class A Extremely Low Risk(X-Ray films)
General NA NA
Class B Low Risk (MRI, digestive catheters)
Controlled 3rd. Party Certification
Regist-ration* Inspe
Class C Medium Risk(artificial bones, dialyzer)
Specially Controlled
MHLW’s Approval
License(Pre-fecture)
ection
dialyzer) fecture)Class D High Risk
(pacemaker, heart valve, VAS, ICD)
* Some exception
Diversity in the Regulation and A l f M di l D iApproval of Medical DevicesJapan: PAL & ICH-GCP
Study Group 3Quality system requirementsQuality system requirements
Study Group 4Quality systems auditing
Study Group 5Clinical evaluation, Clinical EvidenceEvidenceIn-vitro Diagnosis
Global Clinical Trials of Medical DevicesGlobal Clinical Trials of Medical Devices-- Complementary Approach with Global Harmonization Task Force (GHTF) Complementary Approach with Global Harmonization Task Force (GHTF)
and Harmonization by Doing (HBD) and Harmonization by Doing (HBD) --
¤ Clinical Evaluation of Medical DevicesGHTF¤ GHTFGlobal Harmonization Task ForceGlobal Harmonization Task Force
¤ HBDHBDHarmonization by Doing
Juntendo University Medical School 8
8th Kitasato University - Harvard School of Public Health Symposium, September 30, 2008, Tokyo, Japan
HBD: HBD: 実践と調和実践と調和Coordinating Government, Industry, and Academia. All for Patients.Coordinating Government, Industry, and Academia. All for Patients.
規制当局(PMDA, FDA)REGULATORY AUTHORITY
国際整合化会議 実践と調和
REGULATORY AUTHORITY個人 individual国 national世界 global
(3) Harmonization by Doing(3) Harmonization by Doing• Japanese Circulation Society - April 2004
J C A i ti D b 2005• Japanese Coronary Association - December 2005• Think Tank in Tokyo - December 2005• FDA, MHLW, Japanese academia discuss scientific
concerns and regulatory issues – July 2006
Review by FDA and MHLW
FDA MHLW/PMDA DCRISteering
C i JAG AdvaMed JFMDAFDA MHLW/PMDA DCRICommittee
1 Global Cardiovascular Device TrialsGuidance/Suggestion Report/Request
JAG AdvaMed JFMDA
1. Global Cardiovascular Device Trials2. Study on Post Market Registry (Artificial Heart)
3. Clinical Trials Infrastructure/ Methodology
Initial WorkingGroups
124. Regulatory Convergence/Communication
Harmonization by Doing (HBD)Parallel development, application,
i i isubmission and reviewDeveloping clinical infrastructure for the simultaneous/parallel clinical trials in US and JP
Those actions are for the aim of HBD, that is...a s...
Parallel approval and access to brand-new di l d i f US/JP ti t b fit !medical devices for US/JP patients benefit !
• Prospective NIH funded registryP id E h d S ill• Provides Enhanced Surveillance:• AEs, Device Malfunctions
QOL• QOL• Survival
Develops clinical “Best Practices” (reducing• Develops clinical Best Practices (reducing complications)P id f d i i & d ti t• Provides means for designing & conducting post-approval studies in cost efficient wayAll f t t bt i d t f
15
• Allows manufacturers to obtain data from INTERMACs to fulfill post-market requirements
(2)-3 “Next-Generation Medical Devices project” ( ) p jFY2005-2007
Inter-agency Committee for the Guideline Development
METIMHLW
NIHS AIST
METIMHLW
National Institute of Health Sciences
National Institute of Advanced Industrial
Science and Technology
Active Implants WG
Navigation Surgery WG
Drug Delivery System WG
Prosthetic Implants WG
Regenerative Medicine WG
Japan Society for Artificial Organs
Japan Society for Thoracic Surgery
HBD-WG2 Early Discussions• July 2006
– FDA encourages INTERMACS to begin discussions with Japan on collecting Japanese post market MCSD dataJapan on collecting Japanese post-market MCSD data
• October 2006– MHLW and Japanese academia visit INTERMACs
headquarters at UAB • October 2006
– Working Group 2 (Industry Regulators and Academia)Working Group 2 (Industry, Regulators, and Academia) discuss the potential of INTERMACs
• January 2007HBD W t Thi k T k– HBD West Think Tank
• October 2007– Japanese Society of Artificial Organs p y g
(1) INTERMACS(2) Japanese PMS
LVAS RegistryN t G ti MD
July 22, 200817
Next-Generation MDs(3) HBD WG2
AccomplishmentsAccomplishments
• Safety Division of PMDA has – decided to support activities to develop a pp p
Japanese version of INTERMACS to collect, analyze, and provide information pertaining to y , p p gpost-market safety of MCSDs
– set up a steering committee and a workingset up a steering committee and a working group to discuss the issues in detail
July 22, 2008 18
Development of a system to collect and evaluate data for medical devices that require tracking (Draft) (Provisional Translation)
Incorporated Administrative Agency - Pharmaceuticals and Medical Devices Agency (PMDA) Midterm Plan h // d j / li h/ b / df/ k ik k dfhttp://www.pmda.go.jp/english/about/pdf/e-keikaku.pdf
No2. 2 (2) d. For high-risk implantable medical devices that require tracking, such as pacemakers, the Agency, by the end of the Midterm Targets period, shall develop a system to collect and evaluate data regarding the operational status of medical devices as well as failure rates over time.
PMDAContributions to Safety
DB
PMDA’s committeeReport Advise
Measures Steering committee
International registryWorking Group
Contract
Med Report
AccessCooperation
・Harmonization by Doing (HBD)-US Registry(Japan -US) (INTERMACS)
International INTERMACS・ISHLT:MCSD →→ ISHLT Registry
Data coordinating center
Japanese Society for Artificial OrgansJapanese Association for Clinical
Case R
eportical device m
a
Academic Societies
DB(Japanese Registry for VAD) Enrollment
Follow-upProject manager,D
Japanese Association for Clinical Ventricular Assist Systems
The Japanese Association for Thoracic SurgeryThe Japanese Society of Cardiovascular Surgery
The Japanese Circulation SocietyThe Japanese Heart Failure Society
s on alfunctions
Data p(Data entry)
Participating institutions
Data managerBiostatistician, Monitor etc.
Industries
The Japanese College of Cardiology
Data access(own company’s)
Data
Investigation
Data access(own site’s)
HospitalHospitalHospital …IndustriesInformation
Local principal Investigator, Site administrator, CRC etc.
Next stepsNext steps• Develop the protocol for the Japanese registry• Discuss with safety division of PMDA to decide
on data fields that should be capture by the J i tJapanese registry
• Discuss the structure and interface of the J i tJapanese registry
• Discuss dataset structure, programs for data t ti d l iextraction and analysis
• Ensure that the requirements for post-market t di i J t bli h dstudies in Japan are established
• Discuss how data can be used globally with INTERMACS
July 22, 2008 20INTERMACS
Strategy of HBDDoing is Key!
On the Job Training on ProjectsOn the Job Training on ProjectsProof-of-Concept ProjectsAchievable Steps
Build on SuccessAdditional SitesMultiple ProjectsMultiple ProjectsDrugs and DevicesOther Therapeutic AreasOther Therapeutic Areas
Global Clinical Trials of Medical DevicesGlobal Clinical Trials of Medical Devices-- Complementary Approach with Global Harmonization Task Force (GHTF) Complementary Approach with Global Harmonization Task Force (GHTF)
and Harmonization by Doing (HBD) and Harmonization by Doing (HBD) --
¤ Clinical Evaluation of Medical DevicesGHTF¤ GHTFGlobal Harmonization Task ForceGlobal Harmonization Task Force
¤ HBDHBDHarmonization by Doing
Juntendo University Medical School 24
8th Kitasato University - Harvard School of Public Health Symposium, September 30, 2008, Tokyo, Japan